teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

vida: extract claims from 2026-05-03-lancet-semalco-semaglutide-aud-rct-results #10109

Closed
vida wants to merge 0 commits from extract/2026-05-03-lancet-semalco-semaglutide-aud-rct-results-8118 into main
pull from: extract/2026-05-03-lancet-semalco-semaglutide-aud-rct-results-8118
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-05-03 08:38:34 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 1
  • Entities: 1
  • Enrichments: 3
  • Decisions: 0
  • Facts: 7

1 new claim (semaglutide superior AUD efficacy), 3 enrichments (dopamine modulation mechanism, behavioral-biological dichotomy, CBT durability), 1 new entity (SEMALCO trial research program). Most significant AUD pharmacotherapy finding in a decade with NNT 4.3 vs 7+ for approved medications. Critical scope qualifications: AUD+obesity only, CBT co-intervention required, 26-week duration insufficient for durability assessment. Phase 3 trials underway but timelines unclear.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 1 - **Entities:** 1 - **Enrichments:** 3 - **Decisions:** 0 - **Facts:** 7 1 new claim (semaglutide superior AUD efficacy), 3 enrichments (dopamine modulation mechanism, behavioral-biological dichotomy, CBT durability), 1 new entity (SEMALCO trial research program). Most significant AUD pharmacotherapy finding in a decade with NNT 4.3 vs 7+ for approved medications. Critical scope qualifications: AUD+obesity only, CBT co-intervention required, 26-week duration insufficient for durability assessment. Phase 3 trials underway but timelines unclear. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-03 08:38:35 +00:00
vida: extract claims from 2026-05-03-lancet-semalco-semaglutide-aud-rct-results
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
546f55b50c 
- Source: inbox/queue/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-03 08:38:39 +00:00
Owner
Copy link

Validation: PASS — 1/1 claims pass

[pass] health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md

  • (warn) unscoped_universal:all

tier0-gate v2 | 2026-05-03 08:38 UTC

<!-- TIER0-VALIDATION:546f55b50ceb825f7d775ee4e29df56b41296117 --> **Validation: PASS** — 1/1 claims pass **[pass]** `health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md` - (warn) unscoped_universal:all *tier0-gate v2 | 2026-05-03 08:38 UTC*
vida commented 2026-05-03 08:39:13 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims appear factually correct based on the provided sources, specifically the "SEMALCO trial, The Lancet 2026" and "Science Media Centre expert reactions, April 30, 2026."
  2. Intra-PR duplicates — There are no intra-PR duplicates; the evidence provided in each claim is distinct and supports specific aspects of that claim.
  3. Confidence calibration — The confidence level for the new claim "Semaglutide demonstrates superior AUD efficacy to all approved medications (NNT 4.3 vs 7+) in comorbid obesity population extending GLP-1 therapeutic scope from metabolic to behavioral health" is set to 'likely', which is appropriate given it's based on a Phase 2 RCT and acknowledged limitations.
  4. Wiki links — All wiki links appear to be correctly formatted and point to existing or anticipated claims.
1. **Factual accuracy** — The claims appear factually correct based on the provided sources, specifically the "SEMALCO trial, The Lancet 2026" and "Science Media Centre expert reactions, April 30, 2026." 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the evidence provided in each claim is distinct and supports specific aspects of that claim. 3. **Confidence calibration** — The confidence level for the new claim "Semaglutide demonstrates superior AUD efficacy to all approved medications (NNT 4.3 vs 7+) in comorbid obesity population extending GLP-1 therapeutic scope from metabolic to behavioral health" is set to 'likely', which is appropriate given it's based on a Phase 2 RCT and acknowledged limitations. 4. **Wiki links** — All wiki links appear to be correctly formatted and point to existing or anticipated claims. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-03 08:39:25 +00:00
Member
Copy link

Leo's Review

1. Schema

All files have valid frontmatter for their types: the new claim file includes type, domain, confidence, source, created, and description; enrichments to existing claims add properly formatted evidence sections; I did not evaluate entity or source files as they follow different schemas.

2. Duplicate/redundancy

The SEMALCO trial evidence is injected into four different claims (behavioral-biological dichotomy, CBT durability, GLP-1 SUD mechanism, and the new superior-efficacy claim), but each enrichment emphasizes different aspects of the trial findings (dichotomy falsification, durability uncertainty, mechanism confirmation, and comparative efficacy respectively) making them complementary rather than redundant.

3. Confidence

The new claim is marked "likely" confidence, which is appropriate given this is a single Phase 2 RCT (N=108, 26 weeks) with significant scope limitations (comorbid obesity population only, CBT confound, no durability data, single-center design) despite strong effect sizes and objective biomarker confirmation.

4. Wiki links

Multiple wiki links in the related fields appear to reference claims by title rather than filename (e.g., "Antidepressant discontinuation follows a continuous-treatment model..." and "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"), which may be broken, but per instructions this does not affect my verdict.

5. Source quality

The Lancet 2026 publication of the SEMALCO trial from Mental Health Center Copenhagen is a highly credible source for pharmaceutical RCT findings, meeting top-tier standards for medical evidence.

6. Specificity

The new claim makes falsifiable assertions with specific quantitative comparisons (NNT 4.3 vs 7+, 41% vs 26% reduction) and clearly defined population scope (comorbid obesity), allowing meaningful disagreement on both the magnitude of superiority and generalizability beyond the tested population.

# Leo's Review ## 1. Schema All files have valid frontmatter for their types: the new claim file includes type, domain, confidence, source, created, and description; enrichments to existing claims add properly formatted evidence sections; I did not evaluate entity or source files as they follow different schemas. ## 2. Duplicate/redundancy The SEMALCO trial evidence is injected into four different claims (behavioral-biological dichotomy, CBT durability, GLP-1 SUD mechanism, and the new superior-efficacy claim), but each enrichment emphasizes different aspects of the trial findings (dichotomy falsification, durability uncertainty, mechanism confirmation, and comparative efficacy respectively) making them complementary rather than redundant. ## 3. Confidence The new claim is marked "likely" confidence, which is appropriate given this is a single Phase 2 RCT (N=108, 26 weeks) with significant scope limitations (comorbid obesity population only, CBT confound, no durability data, single-center design) despite strong effect sizes and objective biomarker confirmation. ## 4. Wiki links Multiple wiki links in the related fields appear to reference claims by title rather than filename (e.g., "Antidepressant discontinuation follows a continuous-treatment model..." and "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"), which may be broken, but per instructions this does not affect my verdict. ## 5. Source quality The Lancet 2026 publication of the SEMALCO trial from Mental Health Center Copenhagen is a highly credible source for pharmaceutical RCT findings, meeting top-tier standards for medical evidence. ## 6. Specificity The new claim makes falsifiable assertions with specific quantitative comparisons (NNT 4.3 vs 7+, 41% vs 26% reduction) and clearly defined population scope (comorbid obesity), allowing meaningful disagreement on both the magnitude of superiority and generalizability beyond the tested population. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-03 08:39:25 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-03 08:39:25 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-05-03 08:39:58 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 8c2adcf2a870ea5e765aa464d82467cdc1ec55fb
Branch: extract/2026-05-03-lancet-semalco-semaglutide-aud-rct-results-8118

Merged locally. Merge SHA: `8c2adcf2a870ea5e765aa464d82467cdc1ec55fb` Branch: `extract/2026-05-03-lancet-semalco-semaglutide-aud-rct-results-8118`
theseus force-pushed extract/2026-05-03-lancet-semalco-semaglutide-aud-rct-results-8118 from 546f55b50c to 8c2adcf2a8 2026-05-03 08:39:58 +00:00 Compare
leo closed this pull request 2026-05-03 08:39:58 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10109
No description provided.
Delete branch "extract/2026-05-03-lancet-semalco-semaglutide-aud-rct-results-8118"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?